Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785? excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785? is a trademark of Sirigen Group Ltd.

Additional reported applications (for the relevant formats) include: in vivo and in vitro depletion^1,2,7, costimulation of CD3/TCR-mediated signal transduction^3,4, and immunohistochemical staining⁵ of acetone-fixed frozen sections. The 30-H12 antibody does not react with Thy-1.1 alloantigen of the AKR/J and PL strains. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16/CD32, clone 93 (Cat. No. 101301 & 101302) is recommended prior to immunofluorescent staining. The Ultra-LEAF? purified antibody (Endotoxin <0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 105351 & 105352).

1. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
2. Seaman WE. 1983. J. Immunol. 130:1713. (Deplete)
3. Nakashima I, et al. 1991. J. Immunol. 147:1153. (Costim)
4. Nakashima I, et al. 1993. J. Immunol. 151:3511. (Costim)
5. Ledbetter JA, et al. 1980. J. Exp. Med. 152:280. (IHC)
6. Hardy B, et al. 2005. Int. Immunol. 17:615.
7. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
8. Dyer KD, et al. 2007. J. Immunol. 179:1693. (FC) PubMed
9. Sungur CM, et al. 2013. PNAS. 110:7401. PubMed

1. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
2. Wiesner DL, et al. 2020. Cell Host Microbe. 614:27. PubMed
3. Baryawno N et al. 2019. Cell. 177(7):1915-1932 . PubMed
4. Schneider C, et al. 2018. Cell. 174:271. PubMed
5. Han SJ et al. 2017. Immunity. 47(6):1154-1168 . PubMed
6. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
7. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
8. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
9. Huang X, et al. 2020. Cell Host Microbe. 29(2):210-221.e6. PubMed
10. Zhou Y, et al. 2020. Immunity. 52(2):357-373. PubMed
11. Kedage V, et al. 2022. MAbs. 14:2040083. PubMed
12. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
13. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
14. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
15. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
16. Campbell C et al. 2018. Immunity. 48(6):1245-1257 . PubMed
17. Lima-Junior DS, et al. 2021. Cell. . PubMed
18. Borges da Silva H, et al. 2020. Immunity. 53(1):158-171.e6. PubMed
19. Stacy A, et al. 2021. Cell. 184(3):615-627.e17. PubMed
20. Kohn EM, et al. 2022. J Immunol. 208:1417. PubMed
21. Zeis P, et al. 2020. Immunity. 53:775. PubMed
22. Collins N, et al. 2020. Cell. 178(5):1088-1101.e15.. PubMed
23. Baja?a S, et al. 2022. iScience. 25:103732. PubMed
24. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
25. Crinier A, et al. 2018. Immunity. 49:971. PubMed
26. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
27. Severe N et al. 2019. Cell Stem Cell. 25(4):570-583 . PubMed

Hematopoietic stem cells and neurons, all thymocytes, peripheral T cells of the Thy-1.2 bearing mice

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Craig W, et al. 1993. J. Exp. Med. 177:1331.
3. Reif AE and Schlesinger M. 1989. Cell Surface Antigen Thy-1.
4. Mayani H, et al. 1994. Blood 83:2410.